142 related articles for article (PubMed ID: 20039696)
1. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
Guin S; Yao HP; Wang MH
Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
[TBL] [Abstract][Full Text] [Related]
4. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
7. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
9. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
10. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
[TBL] [Abstract][Full Text] [Related]
13. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Suthe SR; Yao HP; Weng TH; Wang MH
Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
Chen JF; Yu BX; Yu R; Ma L; Lv XY; Cheng Y; Ma Q
Oncol Rep; 2017 Feb; 37(2):721-728. PubMed ID: 28075465
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
18. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.
Montero-Julian FA; Dauny I; Flavetta S; Ronsin C; André F; Xerri L; Wang MH; Marvaldi J; Breathnach R; Brailly H
Hybridoma; 1998 Dec; 17(6):541-51. PubMed ID: 9890710
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
